Tag: moderna covid-19

Edesa Biotech NASDAQ EDSA Health Canada COVID19

Edesa Biotech, Inc. (NASDAQ: EDSA) Surges 100% After Receiving Approval to Begin COVID-19 Phase 2/3 Clinical Trials from Health Canada

by admin

June 15, 2020

Edesa Biotech, Inc. (NASDAQ: EDSA) is a clinical-stage biopharmaceutical company that specializes in treatments for dermatological and gastrointestinal ailments. Shares ...

No Result

View All Result

Home
News
Video
Stock and Crypto Screener

Tag: moderna covid-19

Edesa Biotech, Inc. (NASDAQ: EDSA) Surges 100% After Receiving Approval to Begin COVID-19 Phase 2/3 Clinical Trials from Health Canada

Asure Software (NASDAQ: ASUR) is Expanding to Meet the Rising Demand for Human Capital Management Software

OLB Group (NASDAQ: OLB) and Cuentas (NASDAQ: CUEN) Team Up to Bring Fintech Solutions to Over 32,000 Bodegas Across the United States

New Purchase Orders for SD7 Rugged Device, VK7, and Other Accessories Boost Siyata Mobile’s Outlook (NASDAQ: SYTA)

Telcoin (TEL) Quietly Leads a Crypto Remittance Revolution

Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

Safe-T (NASDAQ: SFET) Has Been Selected to Present at the United Nations’ Office of Information and Communications Technology Event

Safe-T Group (NASDAQ: SFET) Reports Fourth Quarter and Full Year 2020 Financial Results

Safe-T Group Ltd. (NASDAQ: SFET) Estimates Record-High Annual Revenues of Approximately $4.9 Million Representing ~50% Growth YoY 2020

JanOne (NASDAQ: JAN) Sells ARCA Recycling Business to VM7, Will Focus on Budding Biopharmaceuticals Business

89bio (NASDAQ: ETNB) Reports Phase 2b ENLIVEN Trial of Pegozafermin Achieved Primary Endpoints For Treatment of Nonalcoholic Steatohepatitis (NASH)

U.S. Xpress Enterprises (NYSE: USX) Enters Into Acquisition Agreement With Knight-Swift Transportation (NYSE: KNX) Valued at $808 Million

Axon Enterprise (NASDAQ: AXON) Maintains its Market Dominance with Strong Growth

Recent News

JanOne (NASDAQ: JAN) Sells ARCA Recycling Business to VM7, Will Focus on Budding Biopharmaceuticals Business

89bio (NASDAQ: ETNB) Reports Phase 2b ENLIVEN Trial of Pegozafermin Achieved Primary Endpoints For Treatment of Nonalcoholic Steatohepatitis (NASH)

Categories

Site Navigation